Literature DB >> 8943097

Preservation of the bystander cytocidal effect of irradiated herpes simplex virus thymidine kinase (HSV-tk) modified tumor cells.

F D Vrionis1, J K Wu, P Qi, W G Cano, V Cherington.   

Abstract

In vitro and animal experiments have demonstrated the potential efficacy of using the bystander effect alone in the treatment of brain tumors. A known problem in some in vitro and in vivo experiments is that a fraction of cells engineered to express the herpes simplex virus thymidine kinase (HSV-tk) gene survive ganciclovir (GCV) treatment and undergo cell division. To prevent the recurrent growth of HSV-tk+ cells in the presence of GCV we examined the potential use of lethal or sublethal irradiation of Walker 256 carcinosarcoma cells selected for expression of the HSV-tk gene (Walker-tk+). Western blot analysis of Walter-tk+ cells showed similar levels of HSV-tk protein expression at 0, 1, 3, 6 and 9 days after lethal gamma-irradiation. In vitro, there was no difference in the bystander effect exerted by non-irradiated, sublethally irradiated or lethally irradiated Walker-tk+ cells on wild-type Walker cells in the presence of GCV. In vivo experiments demonstrated long-term survival (100 days) in rats implanted intrathecally with sublethally or lethally irradiated Walker-tk+ cells with GCV treatments. Intrathecal implantation of irradiated Walker-tk+ cells either pre-mixed with Walker cells or used in in situ treatment of established Walker tumors resulted in prolonged animal survival compared to controls (p < 0.05). These experiments suggest that the bystander tumoricidal effect is preserved despite gamma-irradiation of the HSV-tk modified tumor cells and that irradiation could be an effective method to prevent long-term resistance to GCV in HSV-tk+ tumor cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8943097     DOI: 10.1007/bf00177273

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  25 in total

1.  Computer programs for the analysis of cellular survival data.

Authors:  N Albright
Journal:  Radiat Res       Date:  1987-11       Impact factor: 2.841

2.  In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV tk retroviral gene therapy.

Authors:  W L Bi; L M Parysek; R Warnick; P J Stambrook
Journal:  Hum Gene Ther       Date:  1993-12       Impact factor: 5.695

3.  Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy.

Authors:  F L Moolten
Journal:  Cancer Res       Date:  1986-10       Impact factor: 12.701

4.  An experimental model of retrovirus gene therapy for malignant brain tumors.

Authors:  Y Takamiya; M P Short; F L Moolten; C Fleet; T Mineta; X O Breakefield; R L Martuza
Journal:  J Neurosurg       Date:  1993-07       Impact factor: 5.115

5.  The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified.

Authors:  S M Freeman; C N Abboud; K A Whartenby; C H Packman; D S Koeplin; F L Moolten; G N Abraham
Journal:  Cancer Res       Date:  1993-11-01       Impact factor: 12.701

6.  Retroviral gene transfer induced constitutive expression of interleukin-2 or interferon-gamma in irradiated human melanoma cells.

Authors:  B Gansbacher; K Zier; K Cronin; P A Hantzopoulos; B Bouchard; A Houghton; E Gilboa; D Golde
Journal:  Blood       Date:  1992-12-01       Impact factor: 22.113

7.  In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats.

Authors:  Z Ram; K W Culver; S Walbridge; R M Blaese; E H Oldfield
Journal:  Cancer Res       Date:  1993-01-01       Impact factor: 12.701

8.  Retroviral vector-mediated lymphokine gene transfer into human renal cancer cells.

Authors:  G Gastl; C L Finstad; A Guarini; G Bosl; E Gilboa; N H Bander; B Gansbacher
Journal:  Cancer Res       Date:  1992-11-15       Impact factor: 12.701

9.  Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir.

Authors:  E H Oldfield; Z Ram; K W Culver; R M Blaese; H L DeVroom; W F Anderson
Journal:  Hum Gene Ther       Date:  1993-02       Impact factor: 5.695

10.  In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors.

Authors:  K W Culver; Z Ram; S Wallbridge; H Ishii; E H Oldfield; R M Blaese
Journal:  Science       Date:  1992-06-12       Impact factor: 47.728

View more
  1 in total

Review 1.  Gene therapy of neoplastic meningosis.

Authors:  F D Vrionis
Journal:  J Neurooncol       Date:  1998 Jun-Jul       Impact factor: 4.130

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.